PubRank

Allen C Gao

Author PubWeight™ 69.21‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004 2.82
2 Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 2003 2.79
3 Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet 2005 2.08
4 NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther 2013 1.81
5 Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003 1.80
6 Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol 2005 1.69
7 Stat3 activation in prostatic carcinomas. Prostate 2002 1.61
8 Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2. Clin Cancer Res 2006 1.58
9 Lin28 promotes growth of prostate cancer cells and activates the androgen receptor. Am J Pathol 2013 1.53
10 MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem 2011 1.52
11 Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation. Proc Natl Acad Sci U S A 2006 1.46
12 Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res 2004 1.33
13 Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res 2009 1.32
14 MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One 2012 1.30
15 Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res 2010 1.29
16 Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol 2009 1.26
17 Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers. Mol Cancer Ther 2005 1.26
18 Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 2007 1.23
19 NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Prostate 2008 1.21
20 Selective activation of members of the signal transducers and activators of transcription family in prostate carcinoma. J Urol 2002 1.20
21 RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 2004 1.15
22 Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate 2004 1.14
23 Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate 2012 1.10
24 Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res 2006 1.09
25 Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate 2006 1.07
26 Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells. Prostate 2010 1.05
27 Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. Hum Pathol 2008 1.04
28 Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol Cancer Ther 2013 1.03
29 Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther 2009 1.02
30 Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol 2012 1.02
31 Sanguinarine suppresses prostate tumor growth and inhibits survivin expression. Genes Cancer 2010 1.01
32 Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate 2008 1.00
33 Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives. World J Urol 2011 0.99
34 Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer. Cancer Genomics Proteomics 2005 0.99
35 Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate 2005 0.99
36 Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. Prostate 2013 0.98
37 Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice. Prostate 2002 0.98
38 Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST). Prostate 2014 0.98
39 Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion. Prostate 2011 0.97
40 Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. Genes Cancer 2011 0.96
41 Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Mol Cancer Ther 2007 0.96
42 Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer. Mol Cancer Ther 2006 0.93
43 Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene 2003 0.93
44 Stat3 enhances transactivation of steroid hormone receptors. Nucl Recept 2003 0.92
45 LIGHT, a member of the TNF superfamily, activates Stat3 mediated by NIK pathway. Biochem Biophys Res Commun 2007 0.91
46 Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model. Mol Cancer Ther 2010 0.90
47 Mechanisms of selenium chemoprevention and therapy in prostate cancer. Mol Nutr Food Res 2008 0.87
48 Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells. Cancer Res 2005 0.87
49 RhoGDIα suppresses growth and survival of prostate cancer cells. Prostate 2011 0.86
50 Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells. Endocr Relat Cancer 2014 0.86
51 Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex. Prostate 2012 0.85
52 Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth. Genes Cancer 2010 0.83
53 Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line. Prostate 2007 0.82
54 Effects of triclocarban on intact immature male rat: augmentation of androgen action. Reprod Sci 2010 0.81
55 Interleukin-4 activates androgen receptor through CBP/p300. Prostate 2009 0.81
56 LNCaP prostate cancer cells with autocrine interleukin-6 expression are resistant to IL-6-induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling. Prostate 2011 0.80
57 RhoGDIα downregulates androgen receptor signaling in prostate cancer cells. Prostate 2013 0.80
58 The interleukin 6 receptor is a direct transcriptional target of E2F3 in prostate tumor derived cells. Prostate 2011 0.78
59 STAT3 and transactivation of steroid hormone receptors. Vitam Horm 2005 0.78
60 Intracellular glutathione content influences the sensitivity of lung cancer cell lines to methylseleninic acid. Mol Carcinog 2011 0.77
61 Transcriptional regulation of human RANK ligand gene expression by E2F1. Biochem Biophys Res Commun 2008 0.76
62 Regulation of androgen and vitamin d receptors by 1,25-dihydroxyvitamin D3 in human prostate epithelial and stromal cells. J Urol 2003 0.75
63 [Primary experimental results of methylseleninic acid on the proliferation inhibition and apoptotic induction in human high-metastatic large cell lung cancer cell line L9981]. Zhongguo Fei Ai Za Zhi 2006 0.75
64 Corrigendum: ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med 2016 0.75
65 [Combined Inhibition of Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways in Non-small Cell Lung Cancer Therapy.]. Zhongguo Fei Ai Za Zhi 2009 0.75